List of Excipients in Branded Drug CHILDRENS FEXOFENADINE HYDROCHLORIDE

Generic Drugs Containing CHILDRENS FEXOFENADINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Walgreens Company	fexofenadine hydrochloride	0363-2141	EDETATE DISODIUM
Walgreens Company	fexofenadine hydrochloride	0363-2141	MALTITOL
Walgreens Company	fexofenadine hydrochloride	0363-2141	POLOXAMER 407
Walgreens Company	fexofenadine hydrochloride	0363-2141	POTASSIUM SORBATE
Walgreens Company	fexofenadine hydrochloride	0363-2141	PROPYLENE GLYCOL
Walgreens Company	fexofenadine hydrochloride	0363-2141	SODIUM BENZOATE
Walgreens Company	fexofenadine hydrochloride	0363-2141	SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

What are the Most Frequently-Used Excipients in CHILDRENS FEXOFENADINE HYDROCHLORIDE?

# Of NDCs	Excipient
2	BUTYLPARABEN
5	EDETATE DISODIUM
5	MALTITOL
5	POLOXAMER 407
3	POTASSIUM SORBATE
5	PROPYLENE GLYCOL
2	PROPYLPARABEN

Children’s Fexofenadine Hydrochloride: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

Children’s fexofenadine hydrochloride is a mature, non-sedating antihistamine opportunity with low active-ingredient patent risk and meaningful differentiation potential through formulation design. The strongest commercial levers are palatability, dose accuracy, sugar-free delivery, age segmentation, packaging, and private-label or regional distribution.

The product is a small-molecule oral antihistamine, not a biologic. Biosimilar risk does not apply. Fexofenadine hydrochloride is available in pediatric oral suspensions, tablets, orally disintegrating tablets, and other oral formats. The active ingredient has long been exposed to generic and OTC competition, so commercial value depends primarily on product execution, distribution, brand positioning, and formulation convenience rather than molecule exclusivity.

What is the FDA status of children’s fexofenadine hydrochloride?

Children’s fexofenadine hydrochloride is marketed in the United States as an OTC allergy medicine and through approved prescription and generic product pathways. Fexofenadine hydrochloride was originally approved as Allegra, with later FDA authorization for OTC marketing. Pediatric products use age-specific labeling and dose instructions based on the dosage form and strength.

Regulatory characteristic	Position
Active ingredient	Fexofenadine hydrochloride
Therapeutic class	Second-generation H1 antihistamine
Primary use	Relief of allergy symptoms and chronic urticaria symptoms
Dosage forms	Oral suspension, tablets, orally disintegrating tablets, capsules and related oral products
Pediatric positioning	Depends on product strength, labeling and age group
FDA pathway	OTC labeling and approved drug-product pathways
Biosimilar exposure	None
Generic exposure	High
Current commercial barrier	Formulation, brand, distribution and compliance execution
Core regulatory issue	Pediatric labeling, excipient acceptability, dose accuracy and OTC Drug Facts compliance

The FDA label for children’s fexofenadine products generally covers symptoms such as sneezing, runny nose, itchy or watery eyes, and itching of the nose or throat. Certain products also carry indications for hives associated with chronic idiopathic urticaria. Product labeling differs by dosage form and age range, so a sponsor cannot assume that the label for a tablet applies to a suspension or orally disintegrating product.[1]

What excipients are used in children’s fexofenadine formulations?

The excipient system depends on the delivery format. A liquid suspension needs viscosity control, wetting, sedimentation control, taste masking and preservative protection. A chewable or orally disintegrating tablet needs rapid disintegration, mechanical strength and flavor control. Conventional tablets prioritize low cost, manufacturability and swallowability.

Pediatric oral suspension

A representative children’s fexofenadine oral suspension contains excipients selected from the following functional groups:

Excipient function	Common candidate excipients	Strategic purpose
Suspending agent	Xanthan gum, cellulose derivatives	Controls sedimentation and redispersibility
Buffer	Sodium phosphate salts, citrate systems	Controls pH and supports stability
Wetting or dispersing agent	Polysorbate 80 or related surfactant	Improves dispersion of drug particles
Chelator	Disodium EDTA	Controls trace-metal catalyzed degradation
Sweetener	Sucralose, sorbitol, sucrose or other sweeteners	Masks bitterness
Flavor	Fruit flavors, berry flavors, citrus systems	Improves pediatric acceptance
Preservative	Product-dependent preservative system	Limits microbial growth after opening
Solvent or co-solvent	Purified water, glycerol or propylene glycol where justified	Supports processing and solubilization
Colorant	Optional product-specific color system	Supports product identity and palatability

The commercial objective is not simply to make the active ingredient taste better. The formulation must remain homogeneous long enough for a caregiver to measure an accurate dose, redisperse after storage and retain acceptable taste after repeated use.

Fexofenadine hydrochloride has a characteristic bitter pharmaceutical taste. Sweetener intensity alone may not solve the problem. A better approach is a layered system that combines particle-size control, flavor selection, bitterness suppression and a viscosity profile that limits rapid drug contact with taste receptors.

Orally disintegrating and chewable tablets

Pediatric solid dosage forms may use:

• Mannitol or another polyol for mouthfeel and cooling sensation.
• Microcrystalline cellulose for structure.
• Crospovidone or croscarmellose sodium for rapid disintegration.
• Magnesium stearate or another lubricant.
• Sucralose or high-intensity sweeteners for taste masking.
• Fruit flavors for palatability.
• Colloidal silicon dioxide where needed for flow and moisture control.

Mannitol is commercially attractive because it provides a clean mouthfeel and supports low-moisture processing. It can increase tablet friability if the formulation is not balanced with an appropriate binder and compression profile. Crospovidone often supports rapid breakup without creating excessive gel formation, which is useful for orally disintegrating products.

The main development risk is the tradeoff between rapid disintegration and taste. A tablet that disintegrates immediately may expose fexofenadine to the oral cavity before the flavor system can mask bitterness. Taste-masking technology, coated particles or ion-exchange approaches may create a stronger patent position than a conventional direct-compression formulation.

What excipient strategy is strongest for children’s fexofenadine?

The strongest base strategy is a sugar-free, alcohol-free, low-volume oral suspension with accurate dosing and a differentiated flavor system. A secondary opportunity is a fast-disintegrating tablet for school-age children who can self-administer medication but have difficulty swallowing conventional tablets.

Recommended suspension design

A commercially competitive suspension would target:

1. A concentration that limits administration volume.
2. A viscosity that supports suspension stability without making the product difficult to pour.
3. Rapid redispersion after ordinary household handling.
4. A calibrated oral syringe rather than a household teaspoon.
5. A sugar-free sweetener system.
6. A preservative system compatible with repeated opening.
7. A bottle and closure that reduce residue and dose loss.
8. A flavor profile that is acceptable across repeated daily dosing.

A 6 mg/mL concentration, equivalent to 30 mg per 5 mL, is commercially familiar in children’s allergy products. The concentration can reduce caregiver confusion when compared with less familiar strengths, but the sponsor must avoid look-alike packaging and clearly distinguish age-specific dose instructions.

Sweetener selection

Sucrose improves taste but increases concerns about dental exposure, caloric content and use in children with dietary restrictions. Sucralose can support a sugar-free positioning, but high-intensity sweeteners may leave an aftertaste when used to compensate for severe bitterness.

Polyols can improve mouthfeel but may cause gastrointestinal discomfort at sufficiently high intake. In a low-volume antihistamine product, this risk is usually easier to manage than in high-dose liquid medicines. The final selection should be based on sensory testing, stability and labeled inactive-ingredient requirements rather than cost alone.

Preservative strategy

An aqueous multidose product requires strong microbial-control design. The formulation should be evaluated under antimicrobial effectiveness testing, in-use stability and container-closure studies. Preservative selection can affect taste, pH, regulatory acceptability and consumer perception.

A preservative-free multidose suspension may be commercially attractive but generally requires a more complex package, such as unit-dose containers or a validated dispensing system. Unit-dose packaging can reduce contamination risk and improve portability, but it raises packaging costs and may reduce retail price competitiveness.

What formulations are protected by fexofenadine patents?

Fexofenadine has a mature patent estate. Core composition-of-matter and basic therapeutic patents are no longer the primary commercial barriers in the United States. Generic and OTC competition has been established for years.

Current formulation value is more likely to arise from narrow patents covering:

• Taste-masked fexofenadine particles.
• Specific orally disintegrating tablet compositions.
• Stabilized suspensions.
• Low-sedimentation or rapid-redispersion systems.
• Novel unit-dose packaging.
• Specific combinations of sweetener, flavor and viscosity modifiers.
• Manufacturing processes that improve content uniformity.
• Pediatric dosing devices integrated with the package.
• Selected salts, polymorphs or particle-size distributions, where legally and technically supported.

These patents would not prevent all fexofenadine competition. Their value would depend on whether a competing product can avoid the claimed excipient combination or manufacturing step without losing taste, stability or dose accuracy.

When does children’s fexofenadine lose exclusivity?

The active ingredient has already lost practical exclusivity in the United States. The original Allegra franchise moved from prescription to OTC competition, and multiple generic and store-brand products are available.

Exclusivity category	Commercial position
Active-ingredient exclusivity	Expired or commercially exhausted
Basic composition-of-matter protection	No meaningful current barrier
Pediatric formulation exclusivity	Product-specific and potentially narrow
OTC monograph protection	Does not create conventional brand exclusivity
Trademark protection	Remains relevant to branded products
Formulation patents	May protect specific designs, not the entire active ingredient
Regulatory exclusivity	No broad current exclusivity expected for standard pediatric products

A new sponsor should therefore avoid a business plan that depends on blocking generic fexofenadine. The defensible position must come from a distinct formulation, a superior package, a recognized brand, a pediatric channel strategy or a combination of these factors.

How relevant are Paragraph IV challenges to children’s fexofenadine?

Paragraph IV litigation is historically relevant to generic fexofenadine products, but it is not the primary current risk for a new standard OTC pediatric product. A Paragraph IV certification can challenge an Orange Book-listed patent for an approved drug product. The significance depends on the specific reference product, listed patents, ANDA pathway and timing of any certification.

For a new pediatric formulation, the more practical legal issues are:

• Whether the product is an ANDA, OTC monograph product or approved NDA.
• Whether the product relies on a reference listed drug.
• Whether the formulation contains a patented excipient combination.
• Whether the sponsor’s labeling creates trademark or trade-dress exposure.
• Whether an Orange Book-listed formulation patent is relevant to the proposed product.
• Whether the product has a different indication, strength or dosage form.

Because children’s fexofenadine is a mature market, a sponsor should expect freedom-to-operate work to focus on formulation and packaging patents rather than basic fexofenadine patents. Orange Book status must be checked against the specific reference product and current FDA listing before launch.[2]

What FDA regulatory risks apply to pediatric excipients?

Pediatric excipient risk is concentrated in tolerability, exposure, microbiological control and labeling. An excipient that is acceptable in an adult tablet may be unsuitable for a liquid administered repeatedly to young children.

Key review points include:

Propylene glycol and other co-solvents

Propylene glycol can be useful for solubilization and processing but requires age-appropriate exposure assessment. Its use should be minimized when the product can achieve acceptable performance through particle engineering, surfactants or alternative solvents.

Colorants and flavors

Colorants can increase the risk of allergy-related consumer objections and may reduce international market flexibility. A color-free product can support a clean-label positioning, while a recognizable flavor may be more important for adherence.

Polyols and gastrointestinal tolerance

Sorbitol and related polyols may affect gastrointestinal tolerability at elevated exposure. This is particularly relevant when a child receives multiple medicines containing the same excipient.

Preservatives

Preservatives must be justified by microbiological need and controlled for taste and exposure. A product that fails in-use stability or antimicrobial effectiveness testing can create a major launch delay.

Dosing devices

A dosing syringe should be graduated in the units used on the label. Mismatches between milligrams and milliliters create preventable medication errors. The package should also communicate whether the suspension must be shaken before each dose.

What commercial opportunities exist for children’s fexofenadine?

The market is competitive, but several niches can support differentiated products.

Sugar-free and clean-label products

A sugar-free, dye-free and alcohol-free product can target parents seeking fewer unnecessary ingredients. The claim must be supported by the actual formulation and cannot imply that conventional products are unsafe.

Low-volume suspensions

A more concentrated liquid can reduce administration burden. The tradeoff is that small dosing errors produce larger dose deviations, making syringe design and label clarity critical.

Unit-dose packaging

Single-dose cups, sachets or stick packs can target travel, school and childcare use. They reduce in-use contamination and improve portability but carry higher packaging costs.

Fast-dissolving tablets

An orally disintegrating tablet can address children who dislike liquid medicine or cannot swallow a conventional tablet. It may also reduce shipping weight and improve e-commerce economics.

Pharmacy and private-label products

Fexofenadine is suitable for retailer-branded allergy lines because the active ingredient is established and consumer demand is recurring and seasonal. Contract manufacturing can support private-label launches, although the sponsor must control flavor consistency, supply continuity and packaging quality.

Combination products

Combination products require greater regulatory and clinical scrutiny. Fexofenadine combined with a decongestant, for example, may expand symptom coverage but introduces additional pediatric safety and labeling complexity. A single-ingredient product is easier to position for routine allergy use.

How does children’s fexofenadine compare with competing pediatric antihistamines?

Fexofenadine competes with cetirizine, levocetirizine, loratadine and diphenhydramine products.

Product class	Fexofenadine position
Sedation	Generally positioned as non-drowsy
Taste challenge	Requires meaningful bitterness masking
Pediatric liquid opportunity	Strong, because liquid dosing remains important
Competition	High from cetirizine and loratadine
Differentiation	Flavor, sugar-free formulation, dose volume and packaging
Older sedating products	Compete on price but have a less favorable sedation profile
Biosimilar risk	Not applicable

The strongest commercial message is usually non-drowsy allergy relief combined with a child-acceptable delivery system. Claims must follow the approved or permitted OTC labeling and cannot overstate comparative clinical advantages.

What manufacturing and IP barriers affect launch?

Manufacturing barriers are manageable but technically important. The main risks are:

• Inconsistent particle size and sedimentation.
• Poor content uniformity in low-dose liquid products.
• Flavor drift during shelf life.
• Preservative loss or pH shift.
• Excessive foaming during shaking.
• Bottle residue that reduces delivered dose.
• Tablet friability in orally disintegrating formats.
• Moisture sensitivity during packaging.
• Variation in excipient supply and flavor availability.

A formulation patent has greater practical value when it is difficult to design around while maintaining the same sensory and stability profile. A broad claim to a conventional xanthan-gum suspension is unlikely to create a durable barrier. A narrower claim supported by comparative data, such as improved redispersion after defined storage conditions or superior taste with a specified particle-size distribution, may be more commercially defensible.

What licensing and partnering opportunities exist?

Licensing opportunities are more likely to involve formulation technology, pediatric packaging or regional commercialization than the fexofenadine molecule itself.

Potential deal structures include:

• Licensing a taste-masking platform for antihistamines.
• Acquiring a pediatric suspension formulation from a specialty developer.
• Partnering with a contract manufacturer that has validated liquid OTC capacity.
• Granting regional rights to a branded pediatric product.
• Supplying a retailer with a private-label formulation.
• Licensing a unit-dose or dosing-device design.
• Developing a co-branded product with a pharmacy or consumer-health company.

Because the active ingredient is widely available, supply agreements should address API quality, dual sourcing, seasonal demand and minimum purchase commitments. The commercial value of the formulation will depend on whether the partner controls a differentiated channel or owns a defensible technology.

What generic launch scenarios exist?

Three launch scenarios are realistic.

Standard generic or private-label suspension

This is the lowest-risk path but also the most price-sensitive. Competition is likely to focus on wholesale cost, retail placement and supply reliability. Patent differentiation is limited.

Differentiated pediatric suspension

A sugar-free, low-volume, highly palatable product can command better shelf positioning and potentially higher margins. The sponsor must support the differentiation with sensory, stability and usability data.

Orally disintegrating pediatric tablet

This format may offer stronger product differentiation and lower logistics costs. It carries greater taste-masking and manufacturing risk but can avoid some of the contamination and dosing issues associated with multidose liquids.

Key Takeaways

• Children’s fexofenadine hydrochloride is a mature small-molecule OTC opportunity with no biosimilar risk.
• Core active-ingredient exclusivity is no longer a meaningful commercial barrier.
• Excipient strategy should prioritize taste masking, dose accuracy, suspension stability and repeated-use microbiological control.
• A sugar-free, alcohol-free, low-volume suspension is the most practical lead opportunity.
• Orally disintegrating tablets offer a higher-differentiation alternative for school-age children.
• Formulation patents are likely to be narrow and should focus on taste masking, redispersion, stability, packaging or manufacturing performance.
• Paragraph IV risk is secondary to ordinary generic and private-label competition.
• Commercial value will depend on flavor acceptance, dosing-device usability, retail access and supply reliability.
• The strongest licensing opportunities involve pediatric delivery technology and consumer-health distribution, not the fexofenadine molecule.

FAQs

Is children’s fexofenadine hydrochloride suitable for a sugar-free product?

Yes. A sugar-free formulation can use high-intensity sweeteners, polyols or a combined system. The design must control bitterness, aftertaste, gastrointestinal tolerability and preservative performance.

Can a new fexofenadine suspension obtain meaningful patent protection?

Yes, but protection would likely cover a specific formulation, particle-size range, taste-masking system, packaging configuration or manufacturing process rather than fexofenadine generally.

Is an oral syringe commercially important for pediatric fexofenadine?

Yes. The syringe supports dose accuracy, particularly for concentrated suspensions. Its graduations should match the labeled dose units and the product concentration.

Does fruit juice affect children’s fexofenadine positioning?

Yes. FDA labeling for fexofenadine products warns against taking the medicine with certain fruit juices because they can reduce absorption. Flavor and vehicle development should avoid creating confusion with juice-based administration instructions.[1]

Is a preservative-free children’s fexofenadine product commercially viable?

It can be viable in unit-dose or specialized container systems. A conventional multidose bottle generally requires stronger microbial-control justification and in-use testing.

References

1. U.S. Food and Drug Administration. (n.d.). Children’s Allegra allergy oral suspension: Drug facts and prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Over-the-counter monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs

4. U.S. Food and Drug Administration. (1996). Allegra (fexofenadine hydrochloride) approval information. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/